Merus to Report First Quarter 2017 Financial & Mid-Year Operating Results on July 11, 2017
To participate in the call, please dial (646) 722-4972 (domestic) or (866) 978-9968 (international) and reference conference ID 98331903. A live webcast will be available on the Investors page of the Company's website, http://www.merus.nl. An archived presentation will be available for 90 days.
Merus is a clinical-stage immuno-oncology company developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics®. Biclonics® are based on the full-length IgG format, are manufactured using industry standard processes and have been observed in preclinical studies to have several of the same features of conventional monoclonal antibodies, such as long half-life and low immunogenicity. Merus' lead bispecific antibody candidate, MCLA-128, is expected to begin a Phase 2 clinical trial in the second half of 2017 in two metastatic breast cancer populations. MCLA-128 is also being evaluated in a Phase 1/2 clinical trial in
Eliza Schleifstein+1 973 361 1546 firstname.lastname@example.org Investors: Kimberly Minarovich+1 646 368 8014 email@example.com